Object. The aim of this study was to identify factors associated with delay
ed cranial neuropathy following radiosurgery for vestibular schwannoma (VS
or acoustic neuroma) and to determine how such factors may be manipulated t
o minimize the incidence of radiosurgical complications while maintaining h
igh rates of tumor control.
Methods. From July 1988 to June 1998, 149 cases of VS were treated using li
near accelerator radiosurgery at the University of Florida. In each of thes
e cases, the patient's tumor and brainstem were contoured in 1-mm slices on
the original radiosurgical targeting images. Resulting tumor and brainstem
volumes were coupled with the original radiosurgery plans to generate dose
-volume histograms. Various tumor dimensions were also measured to estimate
the length of cranial nerve that would be irradiated. Patient follow-up da
ta, including evidence of cranial neuropathy and radiographic tumor control
, were obtained from a prospectively maintained, computerized database. The
authors performed statistical analyses to compare the incidence of posttre
atment cranial neuropathies or tumor growth between patient strata defined
by risk factors of interest. One hundred thirty-nine of the 149 patients we
re included in the analysis of complications. The median duration of clinic
al follow up for this group was 36 months (range 18-94 months). The tumor c
ontrol analysis included 133 patients. The median duration of radiological
follow up in this group was 34 months (range 6-94 months).
The overall 2-year actuarial incidences of facial and trigeminal neuropathi
es were 11.8% and 9.5%, respectively. In 41 patients treated before 1994, t
he incidences of facial and trigeminal neuropathies were both 29%, but in t
he 108 patients treated since January 1994, these rates declined to 5% and
2%, respectively.
An evaluation of multiple risk factor models showed that maximum radiation
dose to the brainstem, treatment era (pre-1994 compared with 1994 or later)
, and prior surgical resection were all simultaneously informative predicto
rs of cranial neuropathy risk. The radiation dose prescribed to the tumor m
argin could be substituted for the maximum dose to the brainstem with a sma
ll loss in predictive strength. The pons-petrous tumor diameter was an addi
tional statistically significant simultaneous predictor of trigeminal neuro
pathy risk, whereas the distance from the brainstem to the end of the tumor
in the petrous bone was an additional marginally significant simultaneous
predictor of facial neuropathy risk.
The overall radiological tumor control rate was 93% (59% tumors regressed,
34% remained stable, and 7.5% enlarged), and the 5-year actuarial tumor con
trol rate was 87% (95% confidence interval [CI] 76-98%). Analysis revealed
that a radiation dose cutpoint of 10 Gy compared with more than 10 Gy presc
ribed to the tumor margin yielded the greatest relative difference in tumor
growth risk (relative risk 2.4, 95% Cl 0.6-9.3), although this difference
was not statistically significant (p = 0.207).
Conclusions. Five points must be noted. 1) Radiosurgery is a safe, effectiv
e treatment for small VSs. 2) Reduction in the radiation dose has played th
e most important role in reducing the complications associated with VS radi
osurgery. 3) The dose to the brainstem is a more informative predictor of p
ostradiosurgical cranial neuropathy than the length of the nerve that is ir
radiated. 4) Prior resection increases the risk of late cranial neuropathie
s after radiosurgery. 5) A prescription dose of 12.5 Gy to the tumor margin
resulted in the best combination of maximum tumor control and minimum comp
lications in this series.